Intas Pharmaceuticals
Chinubhai Center, off Nehru Bridge
Ashram Road
Ahmedabad
Gujarat
380 009
Tel: 91-79-26576655
Fax: 91-79-26578862
Website: http://www.intaspharma.com/
13 articles about Intas Pharmaceuticals
-
Following reports of destroyed and discarded data, the U.S. regulator issued a warning letter to India’s Intas Pharmaceuticals regarding violations of current good manufacturing practice.
-
Accord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and Patients
9/20/2022
Accord BioPharma announced today a partnership with StoryMD.
-
Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, CIS and the SEA countries
7/26/2022
Prestige Biopharma Limited and Intas Pharmaceuticals Limited announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige Biopharma’s bevacizumab biosimilar, in the US, Europe, Canada, MENA, Brazil, Mexico, South Africa, Thailand, Vietnam, Philippines, Malaysia, Singapore, Indonesia, Kyrgyzstan and Tajikistan.
-
Accord BioPharma and EVERSANA Announce Partnership to Support the Launch of CAMCEVI® for the Treatment of Advanced Prostate Cancer in Adults in the U.S.
6/29/2022
EVERSANA and Accord BioPharma today announced a partnership to support the recent launch of CAMCEVI ® (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.
-
Comera Life Sciences and Intas Pharmaceuticals Announce Research Collaboration
4/19/2022
Today, Comera Life Sciences, Inc. (“Comera” or the “Company”) and Intas Pharmaceuticals Ltd. (“Intas”) announced a research collaboration to develop a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience.
-
Accord BioPharma, in Partnership with Foresee Pharmaceuticals, Launches CAMCEVI™ (Leuprolide) Injection Emulsion in the U.S. for the Treatment of Advanced Prostate Cancer in Adults
4/4/2022
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd. focused on development of oncology, immunology, and critical care therapies, announced today, in partnership with Foresee Pharmaceuticals Co., Ltd., the U.S. launch of CAMCEVI™ (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.
-
Accord BioPharma Announces New Executive Leadership in Commercialization and Marketing
3/9/2022
Accord BioPharma announced the hire of several key members of its leadership team: George Esgro Jr. as Senior Vice President of Commercial Operations; Kayla Williams as Executive Director of U.S. Portfolio Strategy and Commercial Development; Nuvan Dassanaike as Senior Vice President of Digital and Marketing Strategy & Operations; and Paul Purdy as Vice President and Head of Market Access.
-
The CMA said some pharmaceutical firms charge the NHS with excessively high prices for hydrocortisone tablets and paid off potential competitors to stay out of the market.
-
Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products Enabled by Its Hybrozyme™ Technology
1/7/2021
Alteogen Inc. (KOSDAQ:196170) announced today that it has entered into an exclusive license agreement with Intas Pharmaceuticals Ltd. to use ALT-B4, Alteogen’s novel hyaluronidase – derived utilizing the Hybrozyme™ technology – to develop and commercialize two products. Under the terms of the agreement, Alteogen has granted worldwide rights, except for a few Asian countries, for Intas to develop two products i
-
Intas Pharma on the Prowl for Larger Stake in Teva’s European Ops
8/11/2017
-
Aurobindo, Intas Pharma in Race to Buy Out Teva's UK Biz for $1 Billion
8/29/2016
-
Amarillo Biosciences and Intas Pharmaceuticals Sign License and Supply Agreement to Use Oral Interferon to Treat Influenza in India and Nepal
3/4/2010
-
Amarillo Biosciences Partners With Intas Pharmaceuticals to Treat Influenza in India
10/7/2009